Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17556996 | 0.93 | FAAH (0.41) | FAAHTRPA1KMT2AL3MBTL1CYP2D6 | |
| SCHEMBL17556994 | 0.93 | FAAH (0.41) | FAAHTRPA1KMT2AL3MBTL1CYP2D6 | |
| SCHEMBL15329486 | 0.84 | FAAH (0.41) | FAAHALOX5PPARG | |
| SCHEMBL16056927 | 0.78 | BID (0.44) | FAAHKMT2A | |
| SCHEMBL15329487 | 0.78 | FAAH (0.40) | FAAHPTGESALOX5PPARG | |
| SCHEMBL16057367 | 0.77 | BID (0.47) | FAAH | |
| SCHEMBL16057401 | 0.75 | PTGER1 (0.46) | FAAHKMT2AL3MBTL1 | |
| SCHEMBL14975188 | 0.74 | NAAA (0.47) | FAAHPTGESALOX5PPARG | |
| SCHEMBL15329202 | 0.74 | ALOX5 (0.39) | FAAHKMT2AL3MBTL1ALOX5 | |
| SCHEMBL14975151 | 0.72 | FAAH (0.40) | FAAHPTGESALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | FAAH 2/4885TRPA1 1343/4885KMT2A 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.